Securities Registration (section 12(b)) (8-a12b)
05 Mayo 2016 - 11:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
————————————
FORM 8-A
————————————
FOR REGISTRATION OF CERTAIN CLASSES OF
SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF
THE
SECURITIES EXCHANGE ACT OF 1934
————————————
|
CANCER PREVENTION PHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
|
27-3037551
|
(State of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
1760 East River Road, Suite 250
Tucson, Arizona 85718
(Address of principal executive offices)
(Zip Code)
|
|
Securities to be registered pursuant to Section 12(b) of
the Act:
|
|
|
Title of each class
to be so registered:
|
|
Name of each exchange on which
each class is to be registered:
|
|
|
|
Common Stock, par value $0.001 per share
|
|
NYSE MKT LLC
|
If
this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant
to General Instruction A.(c), check the following box.
þ
If
this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant
to General Instruction A.(d), check the following box.
¨
Securities Act registration statement file number to which this
form relates: 333-208718
Securities to be registered pursuant to Section 12(g) of
the Act:
None
|
Item 1.
|
Description of Registrant’s Securities to be
Registered.
|
Cancer Prevention Pharmaceuticals,
Inc. (the “Registrant”) hereby incorporates by reference herein the description of its Common Stock, par value $0.001
per share, to be registered hereunder, contained under the heading “Description of Our Capital Stock” in the Registrant’s
Registration Statement on Form S-1 (File No. 333-208718), as initially filed with the Securities and Exchange Commission
(the “Commission”) on December 23, 2015, including exhibits, and as amended from time to time thereafter (the “Registration
Statement”). In addition, the above-referenced description included in any prospectus relating to the Registration
Statement filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be
incorporated by reference herein.
In accordance with the “Instructions
as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because
no other securities of the Registrant are registered on the NYSE MKT LLC and the securities registered hereby are not being registered
pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section
12 of the Securities Exchange Act of 1934, the Registrant has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereto duly authorized.
Dated: May 5, 2016
|
|
|
|
CANCER PREVENTION PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Jeffrey Jacob
|
|
|
Name: Jeffrey Jacob
Title: Chief Executive Officer
|
|
|
|
|
|
|
CANCER PREVENTION PHARMACEUTICAL (AMEX:CPP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
CANCER PREVENTION PHARMACEUTICAL (AMEX:CPP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024